Resources

The purpose of this manual is to provide basic information for women to understand the importance of early detection of breast cancer: 1) Recognize risk factors for breast cancer. 2) Learn the importance of the clinical breast exam. 3) Recognize signs and symptoms related to breast cancer, and 4) Know where to go to receive an early detection service.

In low- and middle-income countries (LMICs), too many women are suffering and dying from breast cancer, a cancer which can be successfully treated if detected early. Breast cancer is the leading cause of cancer among women worldwide, with over 2 million new cases estimated in 2020; more than 625,000 women die every year from breast cancer[i]. Most of these deaths occur in LMICs, where late-stage presentation and inaccessible diagnosis and treatment for breast cancer are common.

En los países de ingresos bajos y medianos (PIBM), muchas mujeres sufren y mueren a causa del cáncer de mama, un cáncer que puede tratarse con éxito si se detecta a tiempo.El cáncer de mama es el principal tipo de cáncer que afecta a las mujeres de todo el mundo, con más de 2 millones de casos nuevos estimados en el 2020; muriendo más de 625.000 mujeres cada año por esta causa[i]. La mayoría de estas muertes ocurren en los PIMB, donde son comunes la detección en etapa tardía y el diagnóstico y tratamiento inaccesibles para el cáncer de mama.

This is a comprehensive collection of breast cancer detection training materials, available in English and Spanish. If you're a policymaker, public health practitioner, or health care worker, feel free to use these materials for training and skill-building.

A functional and responsive pharmacovigilance system is an essential element of any health system. After a medicine gains regulatory approval and begins to be used by doctors and patients a pharmacovigilance system will monitor the drug’s safety in real world settings by trying to detect, understand, and prevent adverse drugs reactions and other drug-related problems. PATH & partners have assessed Myanmar’s current pharmacovigilance system using WHO’s criteria is provided, as are results of previous research and recommendations to improve the pharmacovigilance system based on the assessment. Data for the review was gathered from databases (e.g. PubMed, Cochrane Library), WHO, national policy documents, domestic studies, and via key informant interviews.